NCT04088630View on ClinicalTrials.gov

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

June 5, 2024

Conditions
Intracerebral HemorrhageCerebral EdemaStroke HemorrhagicIntracerebral Hemorrhage, HypertensiveIntracerebral Hemorrhage Intraparenchymal
Interventions
DRUG

Fingolimod

A single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset

DRUG

Placebo

A single oral placebo pill within 24 hours of symptom onset

DRUG

Open-label Fingolimod

A single dose of 0.5 mg fingolimod through an NGT or Dobhoff tube within 24 hours of symptom onset

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT04088630 - Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage | Biotech Hunter | Biotech Hunter